Group One Trading
CRVS icon

Group One Trading’s Corvus Pharmaceuticals CRVS Stock Holding History

Group One Trading’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214K Sell
14,300
-56,000
-80% -$777K ﹤0.01% 4235
2026
Q1 		$1.03M Buy
70,300
+16,700
+31% +$267K ﹤0.01% 2691
2025
Q4 		$413K Sell
53,600
-10,900
-17% -$86K ﹤0.01% 3707
2025
Q3 		$475K Buy
64,500
+14,400
+29% +$73.7K ﹤0.01% 3759
2025
Q2 		$200K Sell
50,100
-25,900
-34% -$94.2K ﹤0.01% 4341
2025
Q1 		$242K Sell
76,000
-15,200
-17% -$71.6K ﹤0.01% 3822
2024
Q4 		$488K Buy
91,200
+35,400
+63% +$264K ﹤0.01% 3198
2024
Q3 		$295K Buy
55,800
+29,000
+108% +$104K ﹤0.01% 3279
2024
Q2 		$48.8K Buy
26,800
+20,000
+294% +$37.3K ﹤0.01% 4540
2024
Q1 		$12.1K Sell
6,800
-1,400
-17% -$2.92K ﹤0.01% 5758
2023
Q4 		$14.4K Sell
8,200
-11,000
-57% -$16.1K ﹤0.01% 5969
2023
Q3 		$28K Sell
19,200
-17,200
-47% -$36.4K ﹤0.01% 5610
2023
Q2 		$83.4K Buy
36,400
+35,900
+7,180% +$74.6K ﹤0.01% 4791
2023
Q1 		$455 Sell
500
-4,300
-90% -$3.36K ﹤0.01% 6918
2022
Q4 		$4.08K Sell
4,800
-22,300
-82% -$19.7K ﹤0.01% 6418
2022
Q3 		$22K Sell
27,100
-17,700
-40% -$16.9K ﹤0.01% 6000
2022
Q2 		$44K Buy
44,800
+40,300
+896% +$49.4K ﹤0.01% 5672
2022
Q1 		$7K Sell
4,500
-44,400
-91% -$81.3K ﹤0.01% 7285
2021
Q4 		$118K Sell
48,900
-228,000
-82% -$884K ﹤0.01% 5578
2021
Q3 		$1.34M Buy
276,900
+273,700
+8,553% +$810K ﹤0.01% 3086
2021
Q2 		$9K Buy
3,200
+100
+3% +$275 ﹤0.01% 7552
2021
Q1 		$10K Buy
+3,100
New +$11.2K ﹤0.01% 7043

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Group One Trading's CRVS Position: Q2 2026 in Review

Group One Trading opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 48,292 shares worth $721K. The stake represents ﹤0.01% of the portfolio and ranks #3170 among its holdings. This is a return to the name: Group One Trading previously reported a position in CRVS as recently as Q4 2025.

Group One Trading first reported a position in CRVS in Q3 2020 and has held it in 16 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Group One Trading held 48,292 shares of Corvus Pharmaceuticals worth $721K as of Q2 2026.
  • Corvus Pharmaceuticals was a new Group One Trading position in Q2 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #3170 holding.
  • Group One Trading first reported a position in Corvus Pharmaceuticals in Q3 2020 and has held it in 16 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.